Next-generation therapeutic antibodies for infectious diseases: an alternative to antibiotics

YUMAB' discovery and development platform delivers fully human antibodies using fast and reliable technologies, making it well suited for the development of novel antibody-based solutions in the infectious disease space.

Go to the profile of YUMAB GmbH
Nov 14, 2019
0
0
Page of
Go to the profile of YUMAB GmbH

YUMAB GmbH

YUMAB is a German biotech company that provides the discovery and development of fully human antibodies from world’s largest, natural derived, universal, human antibody libraries (>10e11) and patient specific libraries in combination with powerful in vitro selection technologies. YUMAB’s antibody platform is based on more than 28 years of research and development in recombinant antibody technologies by its founders. With this platform YUMAB generates antibody candidates with natural, close to germ-line sequences for lowest immunogenicity and with pre-designed properties (e.g., interspecies X-reactivity, large epitope coverage or targeted epitopes). The candidates are highly developable into several antibody drug formats like full-length IgGs, Fabs, scFvs, bispecifics, chimeric antigen receptors (CARs), fusion proteins, and antibody drug conjugates (ADCs). YUMAB provides customized solutions from target discovery and production, personalized antibody libraries, optimized antibody discovery strategies (also directly on cells) to close to germline antibody engineering and lead development with high success-rates even to difficult targets like GPCRs. YUMAB offers flexible business models from fee-for-service solutions to collaborative projects. Services are not limited to therapeutic development – it also contains recombinant antibody development for next-generation research and for diagnostic applications.

No comments yet.